AstraZeneca completes equity investment in Cellectis
AstraZeneca has completed an equity investment in Cellectis, a clinical-stage biotechnology company. The Cambridge-based biopharma announced the investment and research collaboration in November 2023, and paid an initial payment of $105million to Cellectis …